Compare NBIX & ELAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NBIX | ELAN |
|---|---|---|
| Founded | 1992 | 1954 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2B | 12.7B |
| IPO Year | 1996 | 2018 |
| Metric | NBIX | ELAN |
|---|---|---|
| Price | $132.03 | $22.34 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 22 | 10 |
| Target Price | ★ $180.91 | $27.89 |
| AVG Volume (30 Days) | 1.1M | ★ 3.7M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 41.95 | N/A |
| EPS | ★ 4.67 | N/A |
| Revenue | $161,626,000.00 | ★ $4,715,000,000.00 |
| Revenue This Year | $24.73 | $8.21 |
| Revenue Next Year | $13.14 | $5.31 |
| P/E Ratio | $28.21 | ★ N/A |
| Revenue Growth | ★ 977.51 | 6.22 |
| 52 Week Low | $108.47 | $9.42 |
| 52 Week High | $160.18 | $27.72 |
| Indicator | NBIX | ELAN |
|---|---|---|
| Relative Strength Index (RSI) | 53.57 | 43.47 |
| Support Level | $124.62 | $22.17 |
| Resistance Level | $135.88 | $22.89 |
| Average True Range (ATR) | 3.50 | 0.76 |
| MACD | 0.08 | -0.08 |
| Stochastic Oscillator | 74.73 | 26.74 |
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.